Applications of the CRISPR-Cas9 system in cancer biology

Nature Reviews Cancer

Volumn 15, Issue 7, 2015, Pages 387-395

  Sánchez Rivera, Francisco J ^a   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; SINGLE STRANDED DNA; ENDONUCLEASE;

ARTICLE; BIOLOGY; CANCER GENETICS; CRISPR CAS SYSTEM; DNA END JOINING REPAIR; DNA MODIFICATION; DNA SEQUENCE; DNA TEMPLATE; DOUBLE STRANDED DNA BREAK; FRAMESHIFT MUTATION; GAIN OF FUNCTION MUTATION; GENE DISRUPTION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; GENETIC ENGINEERING; GENETICS; NEOPLASM; RNA INTERFERENCE; STREPTOCOCCUS PYOGENES; TUMOR GENE;

ANIMALS; CRISPR-CAS SYSTEMS; ENDONUCLEASES; GENES, NEOPLASM; GENES, P53; GENETIC ENGINEERING; HUMANS; MODELS, GENETIC; NEOPLASMS; RNA INTERFERENCE; STREPTOCOCCUS PYOGENES;

EID: 84933277263     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3950     Document Type: Article

References (86)

1. Hanahan D. & Weinberg R. A. The hallmarks of cancer. Cell 100, 57-70 (2000
2. Smithies O., Gregg R. G., Boggs S. S., Koralewski M. A. & Kucherlapati R. S. Insertion of DNA sequences into the human chromosomal β globin locus by homologous recombination. Nature 317, 230-234 (1985
3. Thomas K. R., Folger K. R. & Capecchi M. R. High frequency targeting of genes to specific sites in the mammalian genome. Cell 44, 419-428 (1986
4. Mansour S. L., Thomas K. R. & Capecchi M. R. Disruption of the proto-oncogene Int 2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336, 348-352 (1988
5. Frese K. K. & Tuveson D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658 (2007
6. Rudin N., Sugarman E. & Haber J. E. Genetic and physical analysis of double-strand break repair and recombination in Saccharomyces cerevisiae. Genetics 122, 519-534 (1989
7. Plessis A., Perrin A., Haber J. E. & Dujon B. Site-specific recombination determined by I SceI, a mitochondrial group I intron-encoded endonuclease expressed in the yeast nucleus. Genetics 130, 451-460 (1992
8. Rouet P., Smih F. & Jasin M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl Acad. Sci. USA 91, 6064-6068 (1994
9. Choulika A., Perrin A., Dujon B. & Nicolas J. F. Induction of homologous recombination in mammalian chromosomes by using the I SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. 15, 1968-1973 (1995
10. Bibikova M., Golic M., Golic K. G. & Carroll D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161, 1169-1175 (2002
11. Bibikova M., Beumer K., Trautman J. K. & Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 300, 764 (2003
12. Urnov F. D., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nat. Cell Biol. 435, 646-651 (2005
13. Christian M., et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757-761 (2010
14. Li T., et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res. 39, 359-372 (2011
15. Miller J. C., et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011
16. Hockemeyer D., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011
17. Urnov F. D., Rebar E. J., Holmes M. C., Zhang H. S. & Gregory P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010
18. Joung J. K. & Sander J. D. TALENs: a widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14, 49-55 (2013
19. Cong L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013
20. Mali P., et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013
21. Jinek M., et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013
22. Cho S. W., Kim S., Kim J. M. & Kim J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230-232 (2013
23. Jinek M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012
24. Hsu P. D., et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827-832 (2013
25. Esvelt K. M., et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 10, 1116-1121 (2013
26. Hou Z., et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl Acad. Sci. USA 110, 15644-15649 (2013
27. Doudna J. A. & Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014
28. Vogelstein B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
29. Denicola G. M., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011
30. Kim S., Kim D., Cho S. W., Kim J. & Kim J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012-1019 (2014
31. Lin S., Staahl B. T., Alla R. K. & Doudna J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3, e04766 (2014
32. Malina A., et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 27, 2602-2614 (2013
33. Shalem O., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014
34. Hsu P. D., Lander E. S. & Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014
35. Heyer J., Kwong L. N., Lowe S. W. & Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480 (2010
36. Engelman J. A., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008
37. Chen Z., et al. A murine lung cancer co clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012
38. Wang H., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013
39. Yang H., et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154, 1370-1379 (2013
40. Jackson E. L., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K ras. Genes Dev. 15, 3243-3248 (2001
41. Guerra C., et al. Tumor induction by an endogenous K ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003
42. Findlay G. M., Boyle E. A., Hause R. J., Klein J. C. & Shendure J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120-123 (2014
43. Dow L. E. & Lowe S. W. Life in the fast lane: mammalian disease models in the genomics era. Cell 148, 1099-1109 (2012
44. Chen C., et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25, 652-665 (2014
45. Heckl D., et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941-946 (2014
46. Xue W., et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380-384 (2014
47. Jackson E., et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005
48. Sanchez-Rivera F. J., et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428-431 (2014
49. Maddalo D., et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423-427 (2014
50. Soda M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007
51. Shaw A. T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
52. Blasco R. B., et al. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 9, 1219-1227 (2014
53. Zuris J. A., et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73-80 (2015
54. Platt R. J., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440-455 (2014
55. Yin H., et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541-555 (2014
56. Dow L. E., et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 33, 390-394 (2015
57. Tanenbaum M. E., Gilbert L. A., Qi L. S., Weissman J. S. & Vale R. D. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635-646 (2014
58. Gilbert L. A., et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013
59. Whitworth K. M., et al. Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. Biol. Reprod. 91, 78 (2014
60. Niu Y., et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156, 836-843 (2014
61. Crystal A. S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014
62. Yin H., et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553 (2014
63. Sadelain M., Brentjens R. & Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398 (2013
64. Sadelain M., Papapetrou E. P. & Bushman F. D. Safe harbours for the integration of new DNA in the human genome. Nat. Rev. Cancer 12, 51-58 (2012
65. Bikard D., et al. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429-7437 (2013
66. Gilbert L. A., et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014
67. Mali P., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013
68. Perez-Pinera P., et al. RNA-guided gene activation by CRISPR-Cas9 based transcription factors. Nat. Methods 10, 973-976 (2013
69. Cheng A. W., et al. Multiplexed activation of endogenous genes by CRISPR on, an RNA-guided transcriptional activator system. Cell Res. 23, 1163-1171 (2013
70. Maeder M. L., et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977-979 (2013
71. Konermann S., et al. Genome-scale transcriptional activation by an engineered crispr-Cas9 complex. Nature 517, 583-588 (2014
72. Zalatan J. G., et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339-350 (2015
73. Wang T., Wei J. J., Sabatini D. M. & Lander E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014
74. Koike-Yusa H., Li Y., Tan E. P., Velasco-Herrera M. D. C. & Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267-273 (2013
75. Zhou Y., et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487-491 (2014
76. Chen S., et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015
77. Matano M., et al. Modeling colorectal cancer using CRISPR-Cas9 mediated engineering of human intestinal organoids. Nat. Med. 21, 256-262 (2015
78. Mansour M. R., et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014
79. Choi P. S. & Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat. Commun. 5, 3728 (2014
80. Torres R., et al. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun. 5, 3964 (2014
81. Ghezraoui H., et al. Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol. Cell 55, 829-842 (2014
82. Xiao A., et al. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 41, e141 (2013
83. Canver M. C., et al. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J. Biol. Chem. 289, 21312-21324 (2014
84. Han J., et al. Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9. RNA Biol. 11, 829-835 (2014
85. Ho T. T., et al. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 43, e17 (2014
86. Essletzbichler P., et al. Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res. 24, 2059-2065 (2014